Biocartis

Biocartis is a molecular- and immuno-diagnostics company developing a diagnostics platform. Their are targeting personalized medicine and are developing instruments that look like they can be deployed in both a clinical and diagnostics setting (i.e. a big lab where the samples for analysis are sent to, or right in the doctors office while you wait). They are headquartered in Lausanne, one founder is from EPFL, they were founded in 2007 and they have two subsidiaries in Belgium and the Netherlands.

There are two products described on their webpage, a multiplexing platform is based on DNA/RNA and one that looks to be further behind in development which can also do immunoassays (and appears to be a microfluidics instrument).

In 2011 they report having a small scale production facility up and running and state that they are developing a high volume construction line. Given the large recruiting going on at the Belgium location, it appears they are fairly advanced in test development since they are recruiting people who can look after logistics of test production. And oops, their operational planner job description went up so fast they left some notes in:

• (CGAB : too much duplication : comes back in tasks and Competencies)Strong communication skills to communicate both internally and with customer and suppliers.
• Familiar with Good Warehousing & Material Flow practices in a regulated environment with specific cleanliness and shelf-life requirements
• Capability to establish KPIs internally and with each supplier and monitor performance on a defined frequency.  (CGAB : is already mentioned in the task list)

I wonder who is CGAB...

From the reading of the web, I believe Biocartis is most advanced in developing a test to rapidly evaluate sepsis based on an existing test - SeptiCyte, used in the Australian market. With collaborators (Immunexpress - the original SeptiCyte test developers and Debiopharm) they will adapt the test to their instruments and pass FDA approval (maybe with a commercial launch in 2016?). At least with a validated biomarkers test they won't have to validate the test as well as prove the instrument.